{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:30:42Z","timestamp":1788280242692,"version":"build-2803163510"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2026,3]]},"abstract":"\n Key Points<\/jats:title>\n \n \n \n Dapagliflozin significantly improves renal medullary oxygenation in CKD, constituting a potential mechanism of its nephroprotection.<\/jats:p>\n <\/jats:list-item>\n \n The enhancement of medullary oxygenation is more pronounced in nondiabetic patients, suggesting a distinct pathophysiologic response.<\/jats:p>\n <\/jats:list-item>\n \n Blood oxygenation level\u2013dependent magnetic resonance imaging represents a promising noninvasive biomarker for assessing renal oxygenation.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n Renal hypoxia is believed to play a central role in the pathophysiology of both diabetic and nondiabetic CKD. Dapagliflozin has been shown to slow the progression of kidney disease by counteracting several pathogenic mechanisms. The advent of blood oxygenation level\u2013dependent magnetic resonance imaging (BOLD-MRI) has enabled the noninvasive assessment of renal oxygenation in humans. However, it remains uncertain whether dapagliflozin affects changes in renal oxygenation. The aim of the study was to assess whether dapagliflozin modifies kidney oxygenation measured by BOLD-MRI.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n The GLUcose Transport and Renal PROtection in chronic kidney disease study is a randomized controlled clinical trial investigating the effect of dapagliflozin on kidney measures. Here, we investigate whether changes in global and segmental renal oxygenation estimated by BOLD-MRI (namely, changes in R2* parameter) can be measured, after randomization to dapagliflozin or placebo. We analyzed data from 720 pairs of regions of interest of 20 patients who underwent BOLD-MRI on a 3T magnetic resonance imaging scanner, comparing baseline measurements against the ones obtained after 3 months from the onset of treatment.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n After 12 weeks, dapagliflozin treatment significantly reduced the medullary R2* relaxation rate, indicating improved oxygenation (\n P<\/jats:italic>\n = 0.015), while cortical R2* remained unchanged (\n P<\/jats:italic>\n = 0.56). This effect was more pronounced in nondiabetic patients. Dapagliflozin was identified as the sole independent determinant of improved medullary renal oxygenation (\n \u03b2<\/jats:italic>\n , \u221214.4; 95% confidence interval, \u221223.9 to \u22124.89;\n P<\/jats:italic>\n = 0.003) after accounting for other confounding factors such as age, presence of diabetes or macroalbuminuria, and BP levels. In addition, dapagliflozin appeared to alter the relationship between changes in renal oxygenation and the eGFR slope.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n These findings suggest that dapagliflozin may mitigate medullary hypoxia in patients with CKD. BOLD-MRI could serve as a valuable biomarker for assessing renal functional reserve and predicting CKD progression. Further studies are warranted to confirm these effects and explore underlying molecular mechanisms.<\/jats:p>\n <\/jats:sec>\n \n Clinical Trial registry name and registration number:<\/jats:title>\n EudraCT, 2020-004835-26; ClinicalTrials.gov, NCT05998837.<\/jats:p>\n <\/jats:sec>","DOI":"10.34067\/kid.0000001015","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:03:39Z","timestamp":1762970619000},"page":"535-546","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Dapagliflozin Mitigates Medullary Hypoxia in CKD Patients"],"prefix":"10.34067","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1279-3178","authenticated-orcid":false,"given":"Elisa","family":"Russo","sequence":"first","affiliation":[{"name":"Nephrology, Dialysis and Transplantation Unit, IRCCS Policlinico San Martino, Genoa, Italy"},{"name":"Department of Internal Medicine, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Venturelli","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Di Vincenzo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7018-6367","authenticated-orcid":false,"given":"Lucia","family":"Macci\u00f2","sequence":"additional","affiliation":[{"name":"Nephrology, Dialysis and Transplantation Unit, IRCCS Policlinico San Martino, Genoa, Italy"},{"name":"Department of Internal Medicine, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0834-5586","authenticated-orcid":false,"given":"Pasquale","family":"Esposito","sequence":"additional","affiliation":[{"name":"Nephrology, Dialysis and Transplantation Unit, IRCCS Policlinico San Martino, Genoa, Italy"},{"name":"Department of Internal Medicine, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8264-5318","authenticated-orcid":false,"given":"Francesca","family":"Cappadona","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7449-4718","authenticated-orcid":false,"given":"Giulio","family":"Ferrazzi","sequence":"additional","affiliation":[{"name":"Philips Healthcare, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4420-8691","authenticated-orcid":false,"given":"Rocco","family":"Grillo","sequence":"additional","affiliation":[{"name":"Radiology Department, IRCCS Istituto Giannina Gaslini, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6737-1090","authenticated-orcid":false,"given":"Maria Beatrice","family":"Damasio","sequence":"additional","affiliation":[{"name":"Radiology Department, IRCCS Istituto Giannina Gaslini, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6432-2429","authenticated-orcid":false,"given":"Giacomo","family":"Garibotto","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4219-7043","authenticated-orcid":false,"given":"Francesca","family":"Viazzi","sequence":"additional","affiliation":[{"name":"Nephrology, Dialysis and Transplantation Unit, IRCCS Policlinico San Martino, Genoa, Italy"},{"name":"Department of Internal Medicine, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"issue":"1","key":"B1-20260330","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int Suppl (2011)."},{"issue":"4S","key":"B2-20260330","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int."},{"issue":"9","key":"B3-20260330","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.mpmed.2019.06.010","article-title":"Epidemiology and causes of chronic kidney disease","volume":"47","author":"Noble","year":"2019","journal-title":"Medicine."},{"issue":"10","key":"B4-20260330","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.3390\/biomedicines12102203","article-title":"Chronic kidney disease progression\u2014A challenge","volume":"12","author":"Maringhini","year":"2024","journal-title":"Biomedicines."},{"issue":"9","key":"B5-20260330","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrneph.2014.114","article-title":"Inflammatory processes in renal fibrosis","volume":"10","author":"Meng","year":"2014","journal-title":"Nat Rev Nephrol."},{"issue":"1","key":"B6-20260330","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1681\/ASN.2005070757","article-title":"Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure","volume":"17","author":"Nangaku","year":"2006","journal-title":"J Am Soc Nephrol."},{"issue":"12","key":"B7-20260330","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/archinte.162.12.1401","article-title":"Association of kidney function with anemia: the third national Health and Nutrition Examination Survey (1988-1994)","volume":"162","author":"Astor","year":"2002","journal-title":"Arch Intern Med."},{"issue":"2","key":"B8-20260330","doi-asserted-by":"crossref","first-page":"F282","DOI":"10.1152\/ajprenal.00579.2016","article-title":"Hypoxia-inducible factor-1\u03b1 activation improves renal oxygenation and mitochondrial function in early chronic kidney disease","volume":"313","author":"Thomas","year":"2017","journal-title":"Am J Physiol Renal Physiol."},{"issue":"5","key":"B9-20260330","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2337\/diab.43.5.629","article-title":"Increased renal metabolism in diabetes. Mechanism and functional implications","volume":"43","author":"K\u00f6rner","year":"1994","journal-title":"Diabetes."},{"issue":"10","key":"B10-20260330","first-page":"e46737","article-title":"Anemia and hypoxia impact on chronic kidney disease onset and progression: review and updates","volume":"15","author":"Habas","year":"2023","journal-title":"Cureus."},{"key":"B11-20260330","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3389\/fphys.2016.00667","article-title":"Blood oxygenation level-dependent MRI to assess renal oxygenation in renal diseases: progresses and challenges","volume":"7","author":"Pruijm","year":"2017","journal-title":"Front Physiol."},{"issue":"6","key":"B12-20260330","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1161\/HYPERTENSIONAHA.111.171405","article-title":"Blood oxygen level\u2013dependent magnetic resonance imaging identifies cortical hypoxia in severe renovascular disease","volume":"58","author":"Gloviczki","year":"2011","journal-title":"Hypertension."},{"issue":"4","key":"B13-20260330","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.kint.2017.10.020","article-title":"Reduced cortical oxygenation predicts a progressive decline of renal function in patients with chronic kidney disease","volume":"93","author":"Pruijm","year":"2018","journal-title":"Kidney Int."},{"issue":"7","key":"B14-20260330","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.ekir.2022.04.094","article-title":"Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations","volume":"7","author":"Yau","year":"2022","journal-title":"Kidney Int Rep."},{"issue":"5","key":"B15-20260330","doi-asserted-by":"crossref","first-page":"e167700","DOI":"10.1172\/JCI167700","article-title":"Digging deep into cells to find mechanisms of kidney protection by SGLT2 inhibitors","volume":"133","author":"Tuttle","year":"2023","journal-title":"J Clin Invest."},{"issue":"5","key":"B16-20260330","doi-asserted-by":"crossref","first-page":"771","DOI":"10.34067\/KID.0000000000000425","article-title":"SGLT2 inhibitors and kidney protection: mechanisms beyond tubuloglomerular feedback","volume":"5","author":"Upadhyay","year":"2024","journal-title":"Kidney360."},{"issue":"1","key":"B17-20260330","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S2213-8587(23)00321-2","article-title":"Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial","volume":"12","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"12","key":"B18-20260330","doi-asserted-by":"crossref","first-page":"F1343","DOI":"10.1152\/ajprenal.00007.2015","article-title":"Modeling oxygen consumption in the proximal tubule: effects of NHE and SGLT2 inhibition","volume":"308","author":"Layton","year":"2015","journal-title":"Am J Physiol Renal Physiol."},{"issue":"13","key":"B19-20260330","doi-asserted-by":"crossref","first-page":"e016173","DOI":"10.1161\/JAHA.119.016173","article-title":"Acute and chronic effects of SGLT2 inhibitor empagliflozin on renal oxygenation and blood pressure control in nondiabetic normotensive subjects: a randomized, placebo\u2010controlled trial","volume":"9","author":"Zanchi","year":"2020","journal-title":"J Am Heart Assoc."},{"key":"B20-20260330","doi-asserted-by":"crossref","first-page":"100895","DOI":"10.1016\/j.eclinm.2021.100895","article-title":"Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: a randomised, double-blind, placebo-controlled crossover trial","volume":"37","author":"Laursen","year":"2021","journal-title":"EClinicalMedicine."},{"issue":"10","key":"B21-20260330","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1007\/s00125-024-06228-y","article-title":"Effects of semaglutide, empagliflozin and their combination on renal diffusion-weighted MRI and total kidney volume in patients with type 2 diabetes: a post hoc analysis from a 32 week randomised trial","volume":"67","author":"Vernstr\u00f8m","year":"2024","journal-title":"Diabetologia."},{"issue":"5","key":"B22-20260330","doi-asserted-by":"crossref","first-page":"101274","DOI":"10.1016\/j.diabet.2021.101274","article-title":"Canagliflozin could improve the levels of renal oxygenation in newly diagnosed type 2 diabetes patients with normal renal function","volume":"47","author":"Zhou","year":"2021","journal-title":"Diabetes Metab."},{"issue":"1","key":"B23-20260330","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13098-023-01236-1","article-title":"Sodium-dependent glucose transporter 2 inhibitor alleviates renal lipid deposition and improves renal oxygenation levels in newly diagnosed type 2 diabetes mellitus patients: a randomized controlled trial","volume":"15","author":"Zhang","year":"2023","journal-title":"Diabetol Metab Syndr."},{"issue":"19","key":"B24-20260330","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New Creatinine- and cystatin C-Based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med."},{"issue":"6","key":"B25-20260330","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/ndt\/gfy324","article-title":"Reduced oxygenation but not fibrosis defined by functional magnetic resonance imaging predicts the long-term progression of chronic kidney disease","volume":"35","author":"Sugiyama","year":"2020","journal-title":"Nephrol Dial Transplant."},{"issue":"4","key":"B26-20260330","doi-asserted-by":"crossref","first-page":"R931","DOI":"10.1152\/ajpregu.00552.2010","article-title":"Factors that render the kidney susceptible to tissue hypoxia in hypoxemia","volume":"300","author":"Evans","year":"2011","journal-title":"Am J Physiol Regul Integr Comp Physiol."},{"issue":"4","key":"B27-20260330","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/HYPERTENSIONAHA.119.11684","article-title":"Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors","volume":"75","author":"Wilcox","year":"2020","journal-title":"Hypertension."},{"issue":"4","key":"B28-20260330","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.123.064346","article-title":"Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation."},{"issue":"11","key":"B29-20260330","doi-asserted-by":"crossref","first-page":"F1269","DOI":"10.1152\/ajprenal.00543.2015","article-title":"Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron","volume":"310","author":"Layton","year":"2016","journal-title":"Am J Physiol Renal Physiol."},{"issue":"5","key":"B30-20260330","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00125-023-05876-w","article-title":"Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial","volume":"66","author":"Gullaksen","year":"2023","journal-title":"Diabetologia."},{"issue":"4","key":"B31-20260330","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00592-023-02220-x","article-title":"Assessing early tubular protective effects of SGLT2 inhibitor empagliflozin against type 2 diabetes mellitus using functional magnetic resonance imaging","volume":"61","author":"Zhang","year":"2024","journal-title":"Acta Diabetol."},{"key":"B32-20260330","doi-asserted-by":"crossref","first-page":"1451671","DOI":"10.3389\/fendo.2024.1451671","article-title":"Effects of canagliflozin on kidney oxygenation evaluated using blood oxygenation level-dependent MRI in patients with type 2 diabetes","volume":"15","author":"Mori","year":"2024","journal-title":"Front Endocrinol."},{"issue":"4","key":"B33-20260330","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/jmri.20878","article-title":"What causes diminished corticomedullary differentiation in renal insufficiency?","volume":"25","author":"Lee","year":"2007","journal-title":"J Magn Reson Imaging."},{"issue":"3","key":"B34-20260330","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.kint.2018.05.002","article-title":"A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice","volume":"94","author":"Zhang","year":"2018","journal-title":"Kidney Int."},{"key":"B35-20260330","doi-asserted-by":"crossref","first-page":"154918","DOI":"10.1016\/j.metabol.2021.154918","article-title":"Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease","volume":"126","author":"Liu","year":"2022","journal-title":"Metabolism."},{"issue":"11","key":"B36-20260330","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1111\/dom.14489","article-title":"Changes in plasma and urine metabolites associated with empagliflozin in patients with type 1 diabetes","volume":"23","author":"Liu","year":"2021","journal-title":"Diabetes Obes Metab."},{"key":"B37-20260330","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu Rev Physiol."},{"issue":"5","key":"B38-20260330","doi-asserted-by":"crossref","first-page":"e164486","DOI":"10.1172\/JCI164486","article-title":"SGLT2 inhibitors mitigate kidney tubular metabolic and mTORC1 perturbations in youth-onset type 2 diabetes","volume":"133","author":"Schaub","year":"2023","journal-title":"J Clin Invest."},{"issue":"4","key":"B39-20260330","doi-asserted-by":"crossref","first-page":"F981","DOI":"10.1152\/ajprenal.90757.2008","article-title":"Increased hypoxia and reduced renal tubular response to furosemide detected by BOLD magnetic resonance imaging in swine renovascular hypertension","volume":"297","author":"Gomez","year":"2009","journal-title":"Am J Physiol Renal Physiol."},{"issue":"8","key":"B40-20260330","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.2215\/CJN.02480221","article-title":"Clinical implications of an acute dip in eGFR after SGLT2 inhibitor initiation","volume":"16","author":"Heerspink","year":"2021","journal-title":"Clin J Am Soc Nephrol."}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000001015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:03:26Z","timestamp":1786478606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000001015"}},"subtitle":["Analysis of Blood Oxygenation Level-Dependent Magnetic Resonance Imaging Renal Data from the Randomized Glucose Transport and Renal Protection in CKD Trial"],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000001015","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"2025-04-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}